Incyte stock gets a USD 157 Stifel price target after pipeline update

Published on 10/06/2026 at 13:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Incyte stock closed at USD 114.13 on October 5 after Stifel lifted its target to USD 157. Q2 revenue reached USD 1.674 billion, up 37.7 percent year over year.

Bauhaus-Grafikposter mit geometrischen Primärfarben und dem Text BIOTECH — Bauhaus-Geometrieposter mit Text BIOTECH in Primärfarben symbolisiert den Incyte Biotech-Sektor ISIN US45337C1027, Illustration mit AI erstellt.

Incyte Corporation (ISIN US45337C1027) stock closed at USD 114.13 on Nasdaq on October 5, 2026, down 1.01 percent from the prior session. The immediate catalyst was Stifel raising its price target from USD 145 to USD 157 while keeping a Buy rating, according to Markets Insider on October 5, 2026.

Stifel targets pipeline growth

Stifel analyst Stephen Willey tied the higher target to investor meetings with CEO Bill Meury and upcoming late-stage pipeline data at ESMO and ASH, the same Markets Insider report said. The new target is USD 12 above the previous target, a 8.3 percent increase based on the stated figures.

UBS also raised its target from USD 113 to USD 127 and maintained a Neutral rating on October 5, according to Investing.com. UBS cited the G12D program and Vega Therapeutics assets while warning that research spending could pressure near-term earnings per share.

Q2 revenue reaches USD 1.674 billion

Incyte's second-quarter 2026 revenue rose 37.7 percent year over year to USD 1,674.0 million, while GAAP net income increased 44.6 percent to USD 585.6 million. Diluted EPS reached USD 2.81, compared with USD 2.04 in the year-earlier quarter, according to Financial Report Insights citing the June 30, 2026 filing.

The headline revenue increase included a USD 246.0 million one-time Opzelura Medicaid-rebate reversal, making the underlying sales mix more important than the reported percentage alone. Excluding that item, net product sales increased 17.2 percent to USD 1,242.1 million in the quarter, according to Financial Report Insights.

Consensus remains above the close

MarketBeat lists a Moderate Buy consensus based on 25 analysts, with an average price target of USD 127.45, a high target of USD 157 and a low target of USD 90. The average target stands 11.7 percent above the October 5 close, according to MarketBeat.

That spread leaves the market focused on whether pipeline milestones can offset the higher research burden described by UBS. Incyte's commercial base remains substantial, but the July quarter also showed why one-time accounting effects must be separated from recurring drug demand.

Stock closes below USD 127.45 target

Incyte stock closed at USD 114.13 on Nasdaq on October 5, 2026, within its USD 82.82 to USD 132.60 52-week range. The daily volume was 1,948,659 shares and market capitalization was USD 23.1 billion, giving the October analyst revisions a clear valuation reference.